Navigation Links
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
Date:8/3/2009

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, involved 16 patients who received treatment with Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC).

As of the time of data analysis in April 2009, 10 of the 16 studied patients were alive without evidence of disease progression, of whom eight continued to receive therapy with Stimuvax after 6.3 to 8.2 years. The remaining two living patients discontinued Stimuvax therapy after 2.4 and 5.8 years, respectively, and were without evidence of disease progression. Nine of the 10 living patients had stage IIIb NSCLC upon entry to the trial, while one had stage IV disease. Six of the 10 living patients had a complete response to their first-line chemotherapy or chemo-radiation, while four patients had stable disease. The remaining six of the 16 patients discontinued Stimuvax after 2.0 to 5.1 years of treatment as a result of disease progression and are deceased.

Prolonged treatment with Stimuvax was well-tolerated in this trial. The most common treatment-related adverse events were injection-site reactions, which tended to diminish after the first year of treatment. There was no evidence of autoimmune reactions with prolonged use.

The Phase 2b trial of Stimuvax in patients with stage IIIb/IV NSCLC was conducted by Oncothyreon, with patient enrollment concluding in 2003. Long-term follow-up of these patients was conducted by Merck KGaA of Darmstadt,
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
2. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
3. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon announces closing of $11.1 million registered direct financing
5. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
6. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
7. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Oncothyreon reports first quarter 2009 financial results
9. Oncothyreon regains compliance with NASDAQ listing requirements
10. Oncothyreon to present at Invest Northwest 2009
11. Oncothyreon reports full year and fourth quarter 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
(Date:7/10/2014)... 10, 2014   Ceres, Inc . (Nasdaq: ... announced today financial results for the three months ended ... business. Ceres reported that the company and ... this growing season in Brazil, which concluded in June, ... sorghum evaluation areas for part of the growing season. ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... and LONDON, Nov. 2 A study from Thomson Reuters ... far outpacing research activity in the rest of the world. ... within the next decade. , The study, Global ... collaboration potential of China and its current place in world ...
... Trial , WASHINGTON, Nov. 2 Human Genome ... from BLISS-76, the second of two large-scale phase III ... A full presentation of results from BLISS-52 was ... the American College of Rheumatology. Both trials succeeded ...
... movies, Lucretia Borgia swans around emptying powder from her ring ... usually a confection of gold filigree holding a cabochon or ... contents. It is invariably enormous so large it is ... would have given her eyeteeth for the "smart capsule" devised ...
Cached Biology Technology:China's Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals 2Promise of a New Lupus Treatment Is a Groundbreaking Achievement 2Promise of a New Lupus Treatment Is a Groundbreaking Achievement 3An exquisite container 2An exquisite container 3An exquisite container 4An exquisite container 5
(Date:7/10/2014)... BELL, Pa. , July 2, 2014  Unisys Corporation,s ... Netherlands , Unisys Nederland N.V., today announced that it ... to deliver, implement and manage a new Basic Provision Biometrics ... Unisys won the contract with a solution ... identity management software. The term of the contract is up ...
(Date:7/10/2014)... DUBLIN , July 3, 2014 ... the addition of the "Global Gesture Recognition ... Market - Forecasts to 2020" report to ... Global Gesture Recognition & Touch-Less Sensing ... been around for a while, but the companies ...
(Date:7/10/2014)... , July 9, 2014  Acuity Market Intelligence today released ... 2014 Edition" indicating that the global market for National Electronic ... 2013 to 2018. During this time, the number of National ... 3.5 billion. Asia , with its vast ... National eID cards issued, while Europe ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
... that living a stressful lifestyle can take its toll, making us ... around the office. The same appears to be true of ... published Nov. 10 in the journal Nature , dopamine-releasing neurons ... a lifestyle that requires lots of energy, creating stress that could ...
... a foreign object such as a catheter enters the body, ... a slick coating a biofilm that is highly ... be defeated by a basic approach of conventional means. Instead ... the key players in the network and how they operate. ...
... , The researchers characterize their new technique as a neat ... microscopy, but it,s more like the difference between finding the ... until you fall over it, or using a flashlight. In ... the National Institute of Standards and Technology (NIST) and the ...
Cached Biology News:Stress takes its toll in Parkinson's disease 2Research provides new leads in the case against drug-resistant biofilms 2AFM positioning: Shining light on a needle in a haystack 2
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Yeast tRNA 50 l...
Human monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
...
Biology Products: